metformin has been researched along with Abdominal Obesity in 20 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the effectiveness of exenatide with metformin and sequential treatment with exenatide and glargine added to metformin and their influence on insulin sensitivity and adipose distribution." | 9.27 | Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance. ( Du, X; Hu, C; Lu, W; Lu, Z; Shao, X; Shi, B, 2018) |
| "To study the effect of metformin on metabolic parameters, body weight (BW), and waist circumference (WC) in patients with abdominal obesity (AO)." | 9.19 | [Efficacy of metformin in abdominal obesity]. ( Kichigin, VA; Markova, TN; Mkrtumian, AM; Podachina, SV; Zhuchkova, SM, 2014) |
| "0; 38 females) with abdominal obesity and either impaired fasting glucose, elevated HbA1c, or impaired glucose tolerance (IGT) who were randomized to receive 3-months of exenatide or metformin." | 9.16 | Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. ( Bank, AJ; Bergenstal, RM; Gonzalez-Campoy, JM; Katz, H; Kelly, AS, 2012) |
| "Low birth weight (LBW) followed by a rapid postnatal catch-up in weight predisposes individuals to a central distribution of body fat, which is reverted by metformin." | 8.31 | Circulating GDF15 concentrations in girls with low birth weight: effects of prolonged metformin treatment. ( Bassols, J; Carreras-Badosa, G; de Zegher, F; Díaz, M; Gavaldà-Navarro, A; Ibáñez, L; López-Bermejo, A; Villarroya, F; Villarroya, J, 2023) |
| "To study the effectiveness of exenatide with metformin and sequential treatment with exenatide and glargine added to metformin and their influence on insulin sensitivity and adipose distribution." | 5.27 | Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance. ( Du, X; Hu, C; Lu, W; Lu, Z; Shao, X; Shi, B, 2018) |
| "Prepubertal intervention with metformin reduces central adiposity and improves insulin sensitivity in non-obese catch-up SGA children." | 5.20 | Metformin treatment to reduce central adiposity after prenatal growth restraint: a placebo-controlled pilot study in prepubertal children. ( Bassols, J; de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A, 2015) |
| "To study the effect of metformin on metabolic parameters, body weight (BW), and waist circumference (WC) in patients with abdominal obesity (AO)." | 5.19 | [Efficacy of metformin in abdominal obesity]. ( Kichigin, VA; Markova, TN; Mkrtumian, AM; Podachina, SV; Zhuchkova, SM, 2014) |
| "0; 38 females) with abdominal obesity and either impaired fasting glucose, elevated HbA1c, or impaired glucose tolerance (IGT) who were randomized to receive 3-months of exenatide or metformin." | 5.16 | Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. ( Bank, AJ; Bergenstal, RM; Gonzalez-Campoy, JM; Katz, H; Kelly, AS, 2012) |
| "The BIGPRO1 trial was a 1-year multicentre, randomized, double-blind, controlled clinical trial of metformin versus placebo, carried out in the early 1990s, in 457 upper-body obese non-diabetic subjects with no cardiovascular diseases or contraindications to metformin." | 5.14 | Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial. ( Baccara-Dinet, M; Charles, MA; Diouf, I; Eschwege, E; Fontbonne, A, 2009) |
| "Low birth weight (LBW) followed by a rapid postnatal catch-up in weight predisposes individuals to a central distribution of body fat, which is reverted by metformin." | 4.31 | Circulating GDF15 concentrations in girls with low birth weight: effects of prolonged metformin treatment. ( Bassols, J; Carreras-Badosa, G; de Zegher, F; Díaz, M; Gavaldà-Navarro, A; Ibáñez, L; López-Bermejo, A; Villarroya, F; Villarroya, J, 2023) |
| "Metformin has no significant effect on birthweight percentile in obese pregnant women." | 2.80 | Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial. ( Chiswick, C; Denison, F; Drake, AJ; Forbes, S; Lashen, H; Murray, G; Newby, DE; Norman, JE; Quenby, S; Reynolds, RM; Rodriguez, A; Walker, BR; Weeks, A; Whyte, S; Wray, S, 2015) |
| "Obesity is now a major international health concern." | 2.52 | Obesity and polycystic ovary syndrome. ( Boyle, J; De Courten, B; Joham, A; Naderpoor, N; Shorakae, S; Teede, HJ, 2015) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the Western world comprising a spectrum of liver damage from fatty liver infiltration to end-stage liver disease, in patients without significant alcohol consumption." | 2.50 | Nonalcoholic fatty liver disease and polycystic ovary syndrome. ( Vassilatou, E, 2014) |
| "Colorectal cancer is the third leading cause of cancer death in Japan and the United States and is strongly associated with obesity, especially visceral obesity." | 2.49 | Colon epithelial proliferation and carcinogenesis in diet-induced obesity. ( Endo, H; Hosono, K; Nakajima, A; Takahashi, H, 2013) |
| "Comorbidity, young age, central obesity and poor baseline glycaemic control are important predictors of therapy one year after Type 2 diabetes mellitus debut." | 1.42 | Prescribing practices and clinical predictors of glucose-lowering therapy within the first year in people with newly diagnosed Type 2 diabetes. ( Beck-Nielsen, H; Berencsi, K; Brandslund, I; Christiansen, JS; Friborg, S; Mor, A; Nielsen, JS; Rungby, J; Svensson, E; Sørensen, HT; Thomsen, RW; Vaag, A, 2015) |
| "His parents both had a diagnosis of type 2 diabetes." | 1.39 | Diabetes mellitus with Laron syndrome: case report. ( Agladıoglu, SY; Aycan, Z; Bas, VN; Cetınkaya, S; Kendırcı, HN; Onder, A; Savas Erdeve, S, 2013) |
| " Long-term use of metformin in complex multifactorial therapy of women with decompensated type 2 diabetes DM, AH and abdominal obesity provides improvement of carbohydrate and lipid metabolism, lowering of arterial pressure, diminishment of albuminuria, diastolic dysfunction, and stiffness of left ventricular myocardium." | 1.36 | [Dynamics of structural-functional parameters of cardiovascular system during use of complex therapy of women with type 2 diabetes mellitus]. ( Elsukova, OS; Onuchin, SG; Onuchina, EL; Solov'ev, OV, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.00) | 29.6817 |
| 2010's | 17 (85.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Díaz, M | 2 |
| Carreras-Badosa, G | 1 |
| Villarroya, J | 1 |
| Gavaldà-Navarro, A | 1 |
| Bassols, J | 2 |
| de Zegher, F | 2 |
| López-Bermejo, A | 2 |
| Villarroya, F | 1 |
| Ibáñez, L | 2 |
| Vedire, YR | 1 |
| Mukherjee, S | 1 |
| Dondapati, S | 1 |
| Yendamuri, S | 1 |
| Du, X | 1 |
| Lu, W | 1 |
| Lu, Z | 1 |
| Shao, X | 1 |
| Hu, C | 1 |
| Shi, B | 1 |
| Long, J | 1 |
| Li, L | 1 |
| Wang, F | 1 |
| Yang, G | 1 |
| Cheng, W | 1 |
| Wei, J | 1 |
| Chen, M | 1 |
| Liu, D | 1 |
| Agladıoglu, SY | 1 |
| Cetınkaya, S | 1 |
| Savas Erdeve, S | 1 |
| Onder, A | 1 |
| Kendırcı, HN | 1 |
| Bas, VN | 1 |
| Aycan, Z | 1 |
| Takahashi, H | 1 |
| Hosono, K | 1 |
| Endo, H | 1 |
| Nakajima, A | 1 |
| Glintborg, D | 1 |
| Mumm, H | 1 |
| Altinok, ML | 1 |
| Richelsen, B | 1 |
| Bruun, JM | 1 |
| Andersen, M | 1 |
| Vassilatou, E | 1 |
| Mkrtumian, AM | 1 |
| Markova, TN | 1 |
| Kichigin, VA | 1 |
| Podachina, SV | 1 |
| Zhuchkova, SM | 1 |
| Naderpoor, N | 1 |
| Shorakae, S | 1 |
| Joham, A | 1 |
| Boyle, J | 1 |
| De Courten, B | 1 |
| Teede, HJ | 1 |
| Mor, A | 1 |
| Berencsi, K | 1 |
| Svensson, E | 1 |
| Rungby, J | 1 |
| Nielsen, JS | 1 |
| Friborg, S | 1 |
| Brandslund, I | 1 |
| Christiansen, JS | 1 |
| Vaag, A | 1 |
| Beck-Nielsen, H | 1 |
| Sørensen, HT | 1 |
| Thomsen, RW | 1 |
| Refuerzo, J | 1 |
| Chiswick, C | 1 |
| Reynolds, RM | 1 |
| Denison, F | 1 |
| Drake, AJ | 1 |
| Forbes, S | 1 |
| Newby, DE | 1 |
| Walker, BR | 1 |
| Quenby, S | 1 |
| Wray, S | 1 |
| Weeks, A | 1 |
| Lashen, H | 1 |
| Rodriguez, A | 1 |
| Murray, G | 1 |
| Whyte, S | 1 |
| Norman, JE | 1 |
| Unwin, D | 1 |
| Tobin, S | 1 |
| Fontbonne, A | 1 |
| Diouf, I | 1 |
| Baccara-Dinet, M | 1 |
| Eschwege, E | 1 |
| Charles, MA | 1 |
| Onuchin, SG | 1 |
| Elsukova, OS | 1 |
| Solov'ev, OV | 1 |
| Onuchina, EL | 1 |
| Retnakaran, R | 1 |
| Ye, C | 1 |
| Hanley, AJ | 1 |
| Harris, SB | 1 |
| Zinman, B | 1 |
| Kelly, AS | 1 |
| Bergenstal, RM | 1 |
| Gonzalez-Campoy, JM | 1 |
| Katz, H | 1 |
| Bank, AJ | 1 |
| Carmina, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metformin and Oral Contraceptives in PCOS[NCT00451568] | Phase 4 | 90 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Pilot Randomized Controlled Trial of Spironolactone in Young Women With Nonalcoholic Steatohepatitis (NASH)[NCT03576755] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2019-01-09 | Completed | ||
| Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial[NCT04855513] | 414 participants (Anticipated) | Interventional | 2022-03-24 | Not yet recruiting | |||
| Effect of Metformin on Healthy Live Birth After In-vitro Fertilization in Women With Prediabetes Mellitus: a Multicenter Double-blind Placebo Controlled Randomized Trial[NCT06064669] | 988 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | |||
| Aspirin Versus Metformin in Pregnancies at High Risk of Preterm Preeclampsia: a 3-arm Randomized Controlled Trial[NCT05580523] | 3,000 participants (Anticipated) | Interventional | 2023-07-03 | Recruiting | |||
| The Chronic and Acute Postprandial Vascular Effects of Exenatide vs. Metformin in Abdominally Obese Patients With Impaired Glucose Tolerance[NCT00546728] | Phase 4 | 50 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in reactive hyperemic index over the 3-month treatment period, which is a measure of endothelial (inner lining of blood vessels) function. This is measured as a ratio of post-occlusion blood flow volume versus baseline blood flow volume in fingertips. Higher ratio values are considered indicative of better arterial health. (NCT00546728)
Timeframe: Change from baseline to 3 months
| Intervention | ratio (Mean) |
|---|---|
| Exenatide | 0.01 |
| Metformin | -0.17 |
4 reviews available for metformin and Abdominal Obesity
| Article | Year |
|---|---|
Colon epithelial proliferation and carcinogenesis in diet-induced obesity.
Topics: Aberrant Crypt Foci; Adiponectin; AMP-Activated Protein Kinases; Animals; Cell Proliferation; Cell T | 2013 |
Nonalcoholic fatty liver disease and polycystic ovary syndrome.
Topics: Adiposity; Animals; Caloric Restriction; Comorbidity; Exercise; Female; Humans; Hypoglycemic Agents; | 2014 |
Obesity and polycystic ovary syndrome.
Topics: Adipokines; Bariatric Surgery; Combined Modality Therapy; Comorbidity; Diet, Reducing; Exercise Ther | 2015 |
PCOS: metabolic impact and long-term management.
Topics: Adolescent; Adult; Antihypertensive Agents; Cardiovascular Diseases; Child; Comorbidity; Diabetes Me | 2012 |
9 trials available for metformin and Abdominal Obesity
| Article | Year |
|---|---|
Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance.
Topics: Adiposity; Adult; Aged; Blood Glucose; Body Fat Distribution; Diabetes Mellitus, Type 2; Drug Therap | 2018 |
Screening for a Simple and Effective Indicator of Insulin Resistance in Chinese Reproductive-Aged Women, with the Insulin Clamp Technique as a Reference.
Topics: Adolescent; Adult; Age Factors; Biomarkers; Body Mass Index; China; Cross-Sectional Studies; Diagnos | 2019 |
Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and/or oral contraceptives in polycystic ovary syndrome.
Topics: Abdominal Fat; Absorptiometry, Photon; Adiponectin; Adiposity; Adolescent; Adult; Body Mass Index; C | 2014 |
[Efficacy of metformin in abdominal obesity].
Topics: Adult; Blood Pressure; Body Mass Index; Body Weight; Female; Humans; Hypoglycemic Agents; Insulin Re | 2014 |
Metformin treatment to reduce central adiposity after prenatal growth restraint: a placebo-controlled pilot study in prepubertal children.
Topics: Abdominal Fat; Adiposity; Anti-Obesity Agents; Biomarkers; Body Mass Index; Child; Cohort Studies; D | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Double-Blind Method; Female; Fetal Macrosomia; | 2015 |
Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; | 2009 |
Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance.
Topics: Alanine Transaminase; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Liver; Fema | 2012 |
Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial.
Topics: Aged; Analysis of Variance; Biomarkers; Blood Glucose; C-Reactive Protein; Endothelium, Vascular; Ex | 2012 |
7 other studies available for metformin and Abdominal Obesity
| Article | Year |
|---|---|
Circulating GDF15 concentrations in girls with low birth weight: effects of prolonged metformin treatment.
Topics: Androgens; Birth Weight; Female; Growth Differentiation Factor 15; Humans; Hypoglycemic Agents; Infa | 2023 |
Association between visceral obesity, metformin use, and recurrence risk in early-stage colorectal cancer.
Topics: Adenocarcinoma; Colorectal Neoplasms; Female; Humans; Intra-Abdominal Fat; Male; Metformin; Obesity, | 2023 |
Diabetes mellitus with Laron syndrome: case report.
Topics: Adult; Diabetes Mellitus, Type 2; Disease Susceptibility; Drug Monitoring; Humans; Hypoglycemic Agen | 2013 |
Prescribing practices and clinical predictors of glucose-lowering therapy within the first year in people with newly diagnosed Type 2 diabetes.
Topics: Adult; Age Factors; Aged; Body Mass Index; Cohort Studies; Denmark; Diabetes Mellitus, Type 2; Drug | 2015 |
Metformin and pregnancy outcomes in obese women.
Topics: Diabetes, Gestational; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents; Metformin; Obesity, Ab | 2015 |
A patient request for some "deprescribing".
Topics: Abdominal Pain; Diabetes Mellitus, Type 2; gamma-Glutamyltransferase; Humans; Hypoglycemic Agents; L | 2015 |
[Dynamics of structural-functional parameters of cardiovascular system during use of complex therapy of women with type 2 diabetes mellitus].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Chi-Square Distribution; Data Interpretation, Statis | 2010 |